DrugPatentWatch Database Preview
Indivior Inc Company Profile
What is the competitive landscape for INDIVIOR INC, and what generic alternatives to INDIVIOR INC drugs are available?
INDIVIOR INC has six approved drugs.
There are seventeen US patents protecting INDIVIOR INC drugs.
There are one hundred and eighty-nine patent family members on INDIVIOR INC drugs in twenty-eight countries and one supplementary protection certificate in one country.
Summary for Indivior Inc
| International Patents: | 189 |
| US Patents: | 17 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 6 |
| Patent Litigation for Indivior Inc: | See patent lawsuits for Indivior Inc |
Drugs and US Patents for Indivior Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | 10,058,554 | ➤ Sign Up | ➤ Sign Up | ||||
| Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | 9,180,197 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Indivior Inc | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-004 | Aug 10, 2012 | AB | RX | Yes | Yes | 8,017,150 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Indivior Inc | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-004 | Aug 10, 2012 | AB | RX | Yes | Yes | 8,475,832 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | 9,498,432 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-002 | Nov 30, 2017 | RX | Yes | Yes | 9,782,402 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INDIVIOR INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Film | 2 mg/0.5 mg and 8 mg/2 mg | ➤ Subscribe | 2012-10-15 |
| ➤ Subscribe | Sulingual Film | 12 mg/3 mg | ➤ Subscribe | 2014-03-26 |
| ➤ Subscribe | Sublingual Film | 4 mg/1 mg | ➤ Subscribe | 2013-05-14 |
International Patents for Indivior Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 4795962 | ➤ Sign Up |
| China | 101668519 | ➤ Sign Up |
| Australia | 2006287342 | ➤ Sign Up |
| Australia | 2002332118 | ➤ Sign Up |
| Canada | 2621263 | ➤ Sign Up |
| Mexico | 354603 | ➤ Sign Up |
| Austria | 536868 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Indivior Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0008 | Belgium | ➤ Sign Up | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
